€40 million to accelerate teh development of innovative treatments for early hearing loss
Cilcare completes a €40M series A
The funds will support two Phase 2a clinical trials for the drug candidate CIL001, targeting cochlear synaptopathy (a leading cause of difficulty understanding speech in noise, tinnitus, and hyperacusis), as…
